biomarkers

Exploratory CSF Proteomic Analysis of a Pre-specified pTau217 Subgroup from the SHINE Clinical Trial Identifies Biomarkers Correlated with Cognitive Improvement

Lizama BN, Pandey K, Cho E, et al. Exploratory CSF Proteomic Analysis of a Pre-specified pTau217 Subgroup from the SHINE Clinical Trial Identifies Biomarkers Correlated with Cognitive Improvement in Alzheimer’s Disease Patients Treated with Zervimesine. Poster presented at 2025 Alzheimer’s Association International Conference (AAIC); Toronto, Ontario, Canada

Exploratory CSF Proteomic Analysis of a Pre-specified pTau217 Subgroup from the SHINE Clinical Trial Identifies Biomarkers Correlated with Cognitive Improvement Read More »

Plasma Proteomic Analysis of a Biomarker-defined Subpopulation in the SHINE Ph2 Trial to Identify Molecular Correlates to the Favorable Decrease in GFAP

Lizama BN, DiCaro V, Cho E, et al. Plasma Proteomic Analysis of a Biomarker-defined Subpopulation in the SHINE Ph2 Trial to Identify Molecular Correlates to the Favorable Decrease in the Neuroinflammatory Marker GFAP with Zervimesine in Alzheimer’s Disease Participants. Poster presented at 2025 Alzheimer’s Association International Conference (AAIC); Toronto, Ontario, Canada

Plasma Proteomic Analysis of a Biomarker-defined Subpopulation in the SHINE Ph2 Trial to Identify Molecular Correlates to the Favorable Decrease in GFAP Read More »

Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in ​Mild-to-Moderate AD Patients​

Hamby ME, Kavanagh S, Di Caro V, et al. Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in ​Mild-to-Moderate AD Patients​. Poster presented at AD/PD 2025; Vienna, Austria

Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in ​Mild-to-Moderate AD Patients​ Read More »

Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease

Lizama BN, Pandey K, Duong D, et al. Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease. Poster presented at AD/PD 2025; Vienna, Austria

Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease Read More »

Sigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD)

Lizama BN, Keeling E, Cho E, et al. Sigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD). Sci Rep 15, 4256 (2025). https://doi.org/10.1038/s41598-025-87921-9

Sigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD) Read More »

Exploratory CSF Proteomics Biomarker Outcomes of The Phase 2 Clinical Trial SHINE to Assess The Effects of CT1812 in Alzheimer’s Patients

DiCaro V, Lizama BN, Cho E, et al. Exploratory CSF Proteomics Biomarker Outcomes of The Phase 2 Clinical Trial SHINE to Assess The Effects of CT1812 in Alzheimer’s Patients. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC); Philadelphia, PA.

Exploratory CSF Proteomics Biomarker Outcomes of The Phase 2 Clinical Trial SHINE to Assess The Effects of CT1812 in Alzheimer’s Patients Read More »

Scroll to Top

Thank you for your interest in Cognition’s publications. A PDF of the poster you are interested in will be made available in accordance with the congress’ embargo policy. Please check back soon. 

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.brightfocus.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.preventblindness.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to https://lewybodyresourcecenter.org/

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.lbda.org

You are now leaving the Cognition Therapeutics website

Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.

Continue to www.alz.org